Yatra Pharmaceutical Technology (Shanghai) Co., Ltd. is a Shanghai-based company that specializes in the research and development of innovative pharmaceutical drugs. As a subsidiary of Hepagene Therapeutics, Inc., the company was established in 2016 by its founder, Xiao Dong Xu.

Clinical Trials associated with Hepagene Therapeutics (Sahnghai) Co. Ltd.

CTR20212697

/ CompletedPhase 1

HPG1860在中国健康受试者中单次和多次给药的安全性、耐受性、药代动力学和药效学的I期临床研究

[Translation] A Phase I clinical study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of HPG1860 in healthy Chinese subjects

主要目的：评估中国健康成年受试者单次和多次口服HPG1860药代动力学（PK）特征及安全性，与既往已获得美国成年健康受试者I期临床数据比较，验证HPG1860暴露的种族差异不敏感性，桥接已获得的美国健康受试者PK数据和安全性数据。次要目的：评估中国健康成年受试者单次和多次口服HPG1860的药物效应（PD）特征。

[Translation]

Primary objective: To evaluate the pharmacokinetic (PK) characteristics and safety of HPG1860 after single and multiple oral administration in healthy adult Chinese subjects, and to compare with the previously obtained Phase I clinical data of healthy adult U.S. subjects to verify the insensitivity of racial differences in HPG1860 exposure, and to bridge the PK data and safety data of healthy U.S. subjects. Secondary objective: To evaluate the pharmacodynamic (PD) characteristics of HPG1860 after single and multiple oral administration in healthy adult Chinese subjects.

Start Date15 Dec 2021

Sponsor / Collaborator

Hepagene Therapeutics (Sahnghai) Co. Ltd.

NCT05338034

/ Unknown statusPhase 2

A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis

This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.

Start Date22 Nov 2021

Sponsor / Collaborator

Hepagene Therapeutics (Sahnghai) Co. Ltd.

NCT04480697

/ CompletedPhase 1

A Randomized, Double-Blind, Placebo Controlled, Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HPG1860

This is a randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HPG1860 orally administered in healthy subjects.

Start Date23 Sep 2019

Sponsor / Collaborator

Hepagene Therapeutics (Sahnghai) Co. Ltd.

100 Clinical Results associated with Hepagene Therapeutics (Sahnghai) Co. Ltd.

0 Patents (Medical) associated with Hepagene Therapeutics (Sahnghai) Co. Ltd.

100 Deals associated with Hepagene Therapeutics (Sahnghai) Co. Ltd.

100 Translational Medicine associated with Hepagene Therapeutics (Sahnghai) Co. Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HPG-1860 ( FXR )	Cholangitis, Sclerosing More	Discontinued
HPG-5119 ( GLP-1R )	Obesity More	Discontinued
HPG-3466 ( IAP )	Solid tumor More	Discontinued
HPG-7233 ( THR-β )	Nonalcoholic Steatohepatitis More	Discontinued
HPG-4980	Hepatocellular Carcinoma More	Discontinued

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis